Cited by 99Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people

Open access
Bennett, D A·2005·Journal of Neurology, Neurosurgery & Psychiatry

Abstract

BACKGROUND: The neurobiological changes underlying the association of the apolipoprotein E (APOE) e4 allele with level of cognition are poorly understood. OBJECTIVE: To test the hypothesis that amyloid load can account for (mediate) the association of the APOE e4 allele with level of cognition assessed proximate to death. METHODS: There were 44 subjects with clinically diagnosed Alzheimer's disease and 50 without dementia, who had participated in the Religious Orders Study. They underwent determination of APOE allele status, had comprehensive cognitive testing in the last year of life, and brain autopsy at death. The percentage area of cortex occupied by amyloid beta and the density of tau positive neurofibrillary tangles were quantified from six brain regions and averaged to yield summary measures of amyloid load and neurofibrillary tangles. Multiple regression analyses were used to examine whether amyloid load could account for the effect of allele status on level of cognition, controlling for age, sex, and education. RESULTS: Possession of at least one APOE e4 allele was associated with lower level of cognitive function proximate to death (p = 0.04). The effect of the e4 allele was reduced by nearly 60% and was no longer significant after controlling for the effect of amyloid load, whereas there was a robust inverse association between amyloid and cognition (p = 0.001). Because prior work had suggested that neurofibrillary tangles could account for the association of amyloid on cognition, we next examined whether amyloid could account for the effect of allele status on tangles. In a series of regression analyses, e4 was associated with density of tangles (p = 0.002), but the effect of the e4 allele was reduced by more than 50% and was no longer significant after controlling for the effect of amyloid load. CONCLUSION: These findings are consistent with a sequence of events whereby the e4 allele works through amyloid deposition and subsequent tangle formation to cause cognitive impairment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp.2004.054445

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Relative to the APOEε3 homozygote reference group, carrying one or two APOEε4 alleles is independently associated with a higher Aβ plaque burden and more severe cerebral amyloid angiopathy, whereas APOEε2/ε2 and ε2/ε3 individuals have fewer Aβ plaques but are more likely to have cerebral amyloid angiopathy.

    “Relative to the APOEε3 homozygote reference group, carrying one or two APOEε4 alleles is independently associated with a higher Aβ plaque burden and more severe cerebral amyloid angiopathy (CAA), whereas APOEε2/ε2 and ε2/ε3 individuals have fewer Aβ plaques46–50 but are more likely to have CAA51.”

    From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [46]

    Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • The well-established association between APOE genotype and cognition - whereby APOEε4 accelerates age-related cognitive decline and APOEε2 delays it - is largely mediated by genotype-specific effects on Alzheimer disease neuropathological changes and, to a lesser extent, on comorbid pathologies.

    “The well-established association between APOE genotype and cognition — whereby APOEε4 accelerates age-related cognitive decline76 and APOEε2 delays it77 — is largely mediated by genotype-specific effects on AD neuropathological changes and, to a lesser extent, on comorbid pathologies46–48,78,79.”

    From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [46]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Most studies agree that the APOEε4-linked effect on tau neurofibrillary tangles is primarily indirect, mediated through its increase of Aβ plaque burden.

    “In contrast to Aβ pathology, the existence of a direct effect of APOE genotype on the severity of tau neurofibrillary tangle pathology remains controversial, with most studies agreeing that APOEε4-linked effect on tangles is primarily indirect, mediated through its increase of Aβ plaque burden46–48,53.”

    From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [46]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-5.
  2. Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer's disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003;60:185-9.
  3. Breitner JC, Jarvik GP, Plassman BL, et al. Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Dis Assoc Disord 1998;12:40-4.
  4. Sparks DL, Scheff SW, Liu H, et al. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. J Neurol Sci 1996;138:97-104.
  5. Tiraboschi P, Hansen LA, Masliah E, et al. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004;62:1977-83.
  6. Landen M, Thorsell A, Wallin A, et al. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;61:352-6.
  7. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-35.
  8. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-7.
  9. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta- peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-53.
  10. McNamara MJ, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 1998;55:1001-4.
  11. Gearing M, Mori H, Mirra SS. Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996;39:395-9.
  12. Thaker U, McDonagh AM, Iwatsubo T, et al. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease. Neuropathol Appl Neurobiol 2003;29:35-44.
  13. Ohm TG, Scharnagl H, Marz W, et al. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol (Berl) 1999;98:273-80.
  14. Mukaetova-Ladinska EB, Harrington CR, Roth M, et al. Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. Dement Geriatr Cogn Disord 1997;8:288-95.
  15. Victora CG, Huttly SR, Fuchs SC, et al. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol 1997;26:224-7.
  16. Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load and with clinical Alzheimer's disease and level of cognitive function. Arch Neurol 2004;61:378-84.
  17. Wilson RS, Evans DA, Bienias JL, et al. Proneness to psychological distress and risk of Alzheimer's disease. Neurology 2003;61:1579-85.
  18. Bennett DA, Wilson RS, Schneider JA, et al. Cerebral infarctions and the relation of depressive symptoms to level of cognitive function in older persons. Am J Geriatric Psychiatry 2004;12:211-19.
  19. Wilson RS, Schneider JA, Bienias JL, et al. Depressive symptoms, clinical AD, and cortical plaques and tangles in older persons. Neurology 2003;61:1102-1108.
  20. Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. Psych Aging 2002;17:179-93.
  21. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198-205.
  22. Mitchell TW, Nissanov J, Han LY, et al. Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J Histochem Cytochem 2000;48:1627-38.
  23. Bezdek JC. A convergence theorem for the fuzzy ISODATA clustering algorithm. IEEE Trans Pattern Anal Mach Intell PAMI 1980;2:1-8.
  24. Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment and early Alzheimer's disease. Ann Neurol 2002;51:182-9.
  25. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. TINS 1994;17:525-30.
  26. Pitas RE, Ji ZS, Weisgraber KH, et al. Role of apolipoprotein E in modulating neurite outgrowth: potential effect of intracellular apolipoprotein E. Biochem Soc Trans 1998;26:257-62.
  27. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-37.
  28. Wisniewski T, Castano EM, Golabek A, et al. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994;145:1030-5.
  29. Permanne B, Perez C, Soto C, et al. Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 1997;240:715-20.
  30. Bales KR, Verina T, Cummins DJ, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999;96:15233-8.
  31. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform- dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci SA 2000;97:2892-7.
  32. Holtzman DM, Fagan AM, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000;47:739-747.
  33. NEUROLOGICAL PICTURE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . doi: 10.1136/jnnp.2004.055194 · DOI
  34. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-31.
  35. Lethen H, Flachskampf FA, Schneider R, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol 1997;80:1066-9.
  36. Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septum aneurysm, or both. N Engl J Med 2001;345:1740-6.
  37. Messe SR, Silverman IE, Kizer JR. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004;62:1042-50.

Cited by

Sorted by citations

Authors
Bennett, D. A.
Affiliations
Rush University Medical Center (US)
Corresponding author
Bennett, D A
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2005-09-01
Volume
76
Issue
9
Pages
1194-1199
ISSN
0022-3050 (ISSN-L)
OpenAlex
W2168884540
Cited by
99
References
7
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 7 · 2017: 5 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 7 · 2012: 5
FWCI
4.61
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Rush University
  • Iran Nanotechnology Initiative Council
  • National Institute on Aging (P30-AG 10161, R01 AG15819, R01AG015819, P30AG010161)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, neurofibrillary tangles, tau protein, cognitive function, Alzheimer's disease, mediation, older adults, Religious Orders Study
MeSH terms
Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Amyloid, Apolipoproteins E, Autopsy, Cognition Disorders, Female, Humans, Male, Regression Analysis, Case-Control Studies, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review